Samer Alsaid։ Older Patients With Atrial Fibrillation Benefit From FXI Inhibition
Samer Alsaid, Cardiologist and Vascular Medicine Specialist, shared a post on LinkedIn about a recent article he co-authored with his colleagues, adding:
՛՛Bleeding risk rises steadily with age in patients with atrial fibrillation — underscoring the need for safer anticoagulant options in older individuals.
In our prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, now published in JAMA Cardiology, the FXI inhibitor abelacimab consistently reduced bleeding compared with rivaroxaban across age groups, with the potential for greater absolute reductions in older patients.
FXI inhibition may become a particularly attractive option for older patients with AF, but phase 3 trial results are needed to define its efficacy and overall benefit-risk balance.
Grateful to an outstanding group of collaborators, mentors, and the AZALEA-TIMI 71 investigators who made this work possible․՛՛
Title: Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation
Authors: Samer Al Said, Siddharth M. Patel, Robert P. Giugliano, David A. Morrow, Erica L. Goodrich, Sabina A. Murphy, Bruce Hug, Sanobar Parkar, Shih-Ann Chen, Shaun G. Goodman, Boyoung Joung, Robert G. Kiss, Wojciech Wojakowski, Jeffrey I. Weitz, Dan Bloomfield, Marc S. Sabatine, Christian T. Ruff
Read the Full Article on JAMA Cardiology․

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health